TNFRSF8 and anaplastic large cell lymphoma: CD30 aptamer has excellent performance in the treatment of ALCL, which can effectively increase the retention time of the drug in the target cells and prolong the release time of the drug, as well as specifically target siRNA to ALCL cells to inhibit ALK gene expression, leading to cell growth arrest and death, and has almost no toxic effects on non-targeted cells, these results suggest that CD30 may be a potential tool for targeted therapy against ALCL.